ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
July 15, 2013 7:00 AM UTC
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) gained $1.91 (11%) to $19.40 Independence Day week after the European Commission approved Iclusig ponatinib to treat chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was down $0.05 to $2.45 last week after it resubmitted an NDA to FDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH). The company said it expects a PDUFA date in 1Q14...